Europreneurs MediaBusiness · Startups · The future of Europe
Startups · Denmark

Commit Biologics closes USD 60m seed round to take complement engager to the clinic

The Aarhus University spinout is developing antibodies that direct the complement system, an ancient part of the immune system, against cancer cells and cells that drive autoimmune disease.

The main building of Aarhus University seen from the park amphitheatre in light snow
Photo: Ciara Ní Riain / Wikimedia Commons, CC BY 4.0. Contextual image of Aarhus University, from which Commit Biologics was spun out, photographed in 2021; it does not show the company.

Commit Biologics, a Danish biotech company developing what it calls complement powered immune engagers, has completed a USD 60 million (EUR 54 million) seed financing, it announced on 17 November. The final close was led by Ackermans & van Haaren.

New investors AbbVie Ventures and M Ventures joined existing backers Bioqube Ventures, Korys and Novo Holdings. The round was also reported by EU-Startups.

A seed round built in stages

The USD 60 million figure covers the whole seed round, which has been raised in several steps. Commit emerged from stealth in May 2024 with EUR 16 million from Bioqube Ventures and Novo Holdings, according to its launch announcement. In January 2025 Korys added EUR 5.5 million, bringing the seed total at that point to EUR 21.5 million, the company said in a later release. The final close brings in Ackermans & van Haaren, AbbVie Ventures and M Ventures.

Michael Rosenzweig of AbbVie Ventures, Charlotte Kremers of M Ventures and Lenny Van Steenhuyse of Ackermans & van Haaren join the board.

What Commit is developing

The complement system is a fast acting part of the innate immune system that can kill cells directly. Commit's Bispecific Complement Engager (BiCE) platform uses antibodies that recruit the complement protein C1q to diseased cells, so that complement is activated only where it is needed. The company says the mechanism does not depend on T cells, which sets it apart from the T cell engagers and cell therapies that dominate much of today's immunotherapy. The company expects complement powered immune engagers to become a new pillar of immunotherapy alongside those approaches, EU-Startups reported.

Commit is a spinout from Aarhus University, which has worked on complement biology for about three decades, and was initially incubated by the BioInnovation Institute in Denmark.

From platform to first candidate

The money will fund the completion of IND enabling studies and the filing of an Investigational New Drug application for COM002, Commit's first development candidate, which it announced the previous week. COM002 is a dual targeting BiCE molecule designed to deplete specific immune cells, for patients with cancer and autoimmune disease. Commit will also move a second programme into IND enabling development and expand its pipeline.

"With this financing, we will take COM002, a first-in-class immune engager that works independently of T cells, into the clinic," said chief executive Thomas L. F. Montgomery Andresen. Charlotte Kremers of M Ventures said complement "remains largely untapped in drug development". Lenny Van Steenhuyse of Ackermans & van Haaren pointed to "highly compelling preclinical data in targeted cell depletion".

A busy year for European immunotherapy

Commit's round adds to a series of European immunotherapy and therapeutics financings in 2026. EU-Startups listed Swiss company Nouscom's EUR 120 million raise for cancer immunotherapy and, in Denmark, Breye Therapeutics' EUR 67.5 million round co-led by Novo Holdings, and estimated that the therapeutics deals it had covered this year totalled about EUR 278.5 million before Commit's close.

What it means for founders and investors

A seed round of this size is unusual, but it reflects how biotech financing often works in practice: an initial tranche to prove the platform, extensions as data arrive, and a larger close once a development candidate is chosen. Bringing in corporate venture investors such as AbbVie Ventures also gives Commit potential partners for later stages. For Nordic life science founders, the deal shows that a university platform, an incubator such as the BioInnovation Institute and a strong local anchor investor like Novo Holdings can carry a company to the clinic before a Series A. For more on European biotech funding, see our reports on Vectory's ALS gene therapy round, Traitomic's Series A and SRTD biotech's seed.

Spotted an error? Email contact@europreneursmedia.com and we'll correct it. See our corrections policy and editorial standards.

Keep reading

All news →
Funding

Payhawk raises USD 280m Series C at a USD 2bn valuation

Growth Equity at Goldman Sachs Alternatives led the all-equity round, which doubles the valuation Bulgaria's first unicorn reached in 2022. The company says it is already cash flow positive and has barely touched its last round.

·Payhawk (press release, 18 Nov 2026)